Additional Paid in Capital of ARTELO BIOSCIENCES, INC. from 31 Aug 2016 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
ARTELO BIOSCIENCES, INC. quarterly Additional Paid in Capital in USD history and change rate from 31 Aug 2016 to 31 Dec 2025.
  • ARTELO BIOSCIENCES, INC. Additional Paid in Capital for the quarter ending 31 Dec 2025 was $62,013,000, a 17% increase year-over-year.
Source SEC data
View on sec.gov
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Change (%)

ARTELO BIOSCIENCES, INC. Quarterly Additional Paid in Capital (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $62,013,000 +$8,819,000 +17% 31 Dec 2025 10-K 24 Feb 2026 2025 FY
Q3 2025 $58,491,000 +$5,557,000 +10% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $54,617,000 +$1,892,000 +3.6% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $53,386,000 +$856,000 +1.6% 31 Mar 2025 8-K 11 Jul 2025
Q4 2024 $53,194,000 +$930,000 +1.8% 31 Dec 2024 10-K 24 Feb 2026 2025 FY
Q3 2024 $52,934,000 +$923,000 +1.8% 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 $52,725,000 +$1,471,000 +2.9% 30 Jun 2024 10-Q 13 Aug 2024 2024 Q2
Q1 2024 $52,530,000 +$1,501,000 +2.9% 31 Mar 2024 10-Q 13 May 2024 2024 Q1
Q4 2023 $52,264,000 +$1,589,000 +3.1% 31 Dec 2023 8-K 11 Jul 2025
Q3 2023 $52,011,000 +$2,041,000 +4.1% 30 Sep 2023 10-Q 13 Nov 2023 2023 Q3
Q2 2023 $51,254,000 +$1,930,000 +3.9% 30 Jun 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 $51,029,000 +$2,324,000 +4.8% 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $50,675,000 +$2,555,000 +5.3% 31 Dec 2022 10-K 25 Mar 2024 2023 FY
Q3 2022 $49,970,000 +$21,045,000 +73% 30 Sep 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 $49,324,000 +$22,464,736 +84% 30 Jun 2022 10-Q 09 Aug 2022 2022 Q2
Q1 2022 $48,705,000 +$23,153,158 +91% 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q4 2021 $48,120,000 +$28,228,650 +142% 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q3 2021 $28,925,000 +$15,653,000 +118% 31 Aug 2021 10-K 31 Mar 2023 2022 FY
Q2 2021 $26,859,264 +$15,249,998 +131% 31 May 2021 10-Q 12 Jul 2021 2021 Q3
Q1 2021 $25,551,842 +$14,375,929 +129% 28 Feb 2021 10-Q 13 Apr 2021 2021 Q2
Q4 2020 $19,891,350 +$8,820,833 +80% 30 Nov 2020 10-Q 14 Jan 2021 2021 Q1
Q3 2020 $13,272,000 +$2,993,579 +29% 31 Aug 2020 10-KT 21 Mar 2022 2022 Q1
Q2 2020 $11,609,266 +$7,501,606 +183% 31 May 2020 10-Q 13 Jul 2020 2020 Q3
Q1 2020 $11,175,913 +$8,252,496 +282% 29 Feb 2020 10-Q 13 Apr 2020 2020 Q2
Q4 2019 $11,070,517 +$8,357,036 +308% 30 Nov 2019 10-Q 14 Jan 2020 2020 Q1
Q3 2019 $10,278,421 +$7,764,285 +309% 31 Aug 2019 10-K 04 Nov 2020 2020 FY
Q2 2019 $4,107,660 +$2,251,635 +121% 31 May 2019 10-Q 15 Jul 2019 2019 Q3
Q1 2019 $2,923,417 +$1,348,378 +86% 28 Feb 2019 10-Q 15 Apr 2019 2019 Q2
Q4 2018 $2,713,481 +$1,858,313 +217% 30 Nov 2018 10-Q 14 Jan 2019 2019 Q1
Q3 2018 $2,514,136 +$1,686,194 +204% 31 Aug 2018 10-K/A 18 Dec 2019 2019 FY
Q2 2018 $1,856,025 +$1,800,409 31 May 2018 10-Q 13 Jul 2018 2018 Q3
Q1 2018 $1,575,039 28 Feb 2018 10-Q/A 14 May 2018 2018 Q2
Q4 2017 $855,168 30 Nov 2017 10-Q/A 21 Mar 2018 2018 Q1
Q3 2017 $827,942 +$789,182 31 Aug 2017 10-K 29 Nov 2018 2018 FY
Q2 2017 $55,616* 31 May 2017 10-Q 21 Jul 2017 2017 Q3
Q3 2016 $38,760* 31 Aug 2016 10-K 29 Nov 2017 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.